AAC system, 339, 340
AAC, 340
AAV gene therapy, 181, 217, 234
AAV, 233
aberrant, 169
actin dynamics, 192
activated phenotype, 172
activity, 329, 331
aggregation, 141, 143, 147, 157, 159, 175, 201, 225
airway protection, 314
ALS/PDC, 202
ALS2/alsin, 199
ALSFRS-R, 266, 267, 269, 270, 275, 276, 284, 287, 292, 320, 333
ALS-FTD, 152, 176, 185, 187, 192, 198, 240, 260, 303
alternative route feeding, 312
AMX0035, 276
anatomical progression, 179, 249, 260
animal model, 146, 160, 161, 170, 173, 177, 234, 240, 305
antibodies, 224, 237
antisense, 220, 221
ANXA11, 121, 156, 196
arimoclomol, 271
artificial intelligence, 113, 243
assistive technology, 113, 308, 336
astrocyte, 164, 172, 215, 223
astrocyte/MN co-cultures, 243
atrophy, 248, 260
autophagy, 126, 143, 146, 227, 228, 234
axon degeneration, 177
axonal transport, 150, 177
Bangladesh, 295
Beclin1, 227
behaviour and cognition, 303, 306
big data, 102, 106, 107, 265, 268, 278
bioenergetic nanocatalysis, 239
bioinformatics, 102, 103, 106, 108, 130, 216
biomarker, 188, 206, 207, 208, 210, 212, 213, 215, 217, 248, 250, 254, 256, 264, 281, 286, 291, 292
blood-brain barrier, 269
body composition, 309
bone marrow, 231
brain delivery system, 233
bulbar muscle weakness, 322
bulbar, 297, 337, 338
C9orf72, 114, 117, 128, 162, 184, 190, 191, 192
calcium, 140, 156, 157
care team, 345
caregiver, 262, 307, 308, 335
causes, 135
CD34, 241
cerebellum, 261
cfDNA, 216
Charcot-Marie-Tooth disease, 115
CHCHD10, 200
chitinases, 213
chlorovirus, 168
CHMP2B, 187
circadian rhythm, 329
clinical care, 285, 344, 345, 346
clinical genetic testing, 114
clinical tool, 115
clinical trial, 262, 264, 266, 270, 271, 272, 273, 275, 278, 282, 283, 285, 286, 288
clinician-patient communication, 329
clinicopathological correlation, 290
CMAP scan, 246
CMCT, 253
cognition, 116, 301, 302, 303, 306
cognative
change, 301
impairment, 256, 302, 303, 304, 306, 338
reserve, 302
screening, 306
combination therapy, 166
communication guide, 346
communication, 298, 308, 340, 346
complement system, 168
continuing employment, 334
copper, 201, 205
cortex, 154
cortical dysfunction, 179, 227, 294
cortical hyperexcitability, 164, 252, 254
cortical neuron, 190
corticomuscular coherence, 255
Corticospinal neurodegeneration, 179
corticospinal, 217, 253, 255
cough, 314, 318, 319, 322
CRISPR/Cas9, 137, 138, 228
cross-sectional survey, 320
CSF, 208, 209, 210
CuATSM, 179, 205, 223, 283, 284, 294
cyclin F, 193
cytoplasmic dynein, 143
D50 model, 269
Date of onset, 266
de novo, 128
degeneration, 178, 212
depression, 302, 305
DHX30, 194
diagnosis, 217, 289, 329
diaphragm pacing, 322
diaphragm, 322
diet, 310
diffusion, 257
Diffusion-Tensor-Imaging, 258
digital health, 268
dipeptide repeat protein, 149
direct reprogramming, 139
disease burden, 263, 273, 299, 342
mechanisms, 119
modeling,108, 136, 141, 150, 181, 195, 218, 265
onset, 115, 276
progression, 110, 112, 133, 201, 212, 258, 267, 268, 275, 276, 292, 293, 296, 299, 325
subtypes, 295
DNA damage, 176, 192
DNA methylation, 211, 216
DPR-related phenotypes, 191
driving, 333
Drosophila, 175, 185
drug development, 218, 225, 227, 229, 232, 233, 236, 239, 243, 244, 276, 284, 288
dysphagia, 313, 322, 336, 337, 338, 343
dysphasia, 305, 338
ECAS, 302, 306
ECG/EEG/EMG, 246, 255, 256
edaravone, 264, 274, 284, 285, 286, 287, 288, 345
education, 262, 289, 340, 342
efficacy endpoints, 269
electromagnetic fields, 253
electrophysiology, 146, 247, 248, 249, 254
end of life, 347
endosome, 185
endpoint, 270
energy metabolism, 168, 173, 174
enrollment, 262
environmental factors, 181
epidemiology, 101, 102, 103, 104, 105, 106, 107, 111, 112, 125, 295
ER stress, 135
etiology, 324
excitability, 165, 194, 248
excitotoxicity, 166, 172
exercise, 331, 332
exome sequencing, 119
exome, 119
exosome, 154, 203, 215
expiratory training, 316
exploratory biomarkers, 212
extracellular vesicles, 175
extraocular muscle, 175
FALS, 119, 297, 327
fasciculation, 250, 251, 252
fibroblasts, 139
Foreign Accent Syndrome, 298
FORTITUDE-ALS, 275
FT9, 109
FTD, 114, 117, 200, 301
FUS, 146, 164, 194, 195, 220, 222, 235
FVC, 315, 316, 318
F-wave, 248
gastrostomy, 311
gene, 121, 124
discovery, 135
expression, 118, 157
regulation, 157, 181
therapy, 219, 231, 233
gene-environment interaction, 149
genetic counselling, 125, 327
genetic modifiers, 137
genetic testing, 115, 117, 123, 124, 290, 327
genetics, 101, 120, 121, 122, 123, 126, 130, 132, 133, 160, 189, 197
genome, 119
genomics, 117
genotype-phenotype, 297
genotyping, 128
geospatial, 103
glia, 175, 214
GLT8D1, 124, 197
glutamate metabolism, 206
Golgi apparatus, 136
Golgi fragmentation, 166
growth factors, 231
GWAS, 116
handedness, 251
healthcare, 185
heterogeneity, 188, 189, 269, 295
hexanucleotide repeat, 185
High-Resolution Impedance Manometry, 337
histone deacetylase, 235
home based measures, 268
human iPS astrocytes/neurons, 194, 196
human iPSC, 189, 191
human therapeutic screens, 294
hydration and dehydration, 313
hypermetabolism, 238
hypoventilation symptoms, 318
hypoventilation, 316, 323
identity-by-descent, 129
IL-6, 215
imaging, 257, 259, 294
immune system, 197, 214, 278
in vitro, 135, 141, 155, 158, 159, 294
in vivo model, 164
in vivo, 185, 229
incidence, 104, 105
inflammasome, 242
inflammation, 151, 184, 214, 283
interneurons, 227
intervention trial, 276
intervention, 308
iPSC model, 240
iPSC, 140, 141, 188, 190
iron, 223
isometric muscle strength, 299
KIF5A, 120
laminin, 230
Laser ablation-ICP-MS, 179
Levosimendan, 272
Lipid metabolism, 172
lung volume recruitment, 315
machine learning, 108
malignancy, 254
management, 328, 334, 341
map, 107
Masitinib, 242, 273
Matrin-3, 140
medical coordinator, 341
Mendelian randomization, 101
meninges, 151
mesenchymal stem cells, 141
metabolism, 173, 206, 235, 313
metal ions, 179
microbiome, 206, 282
microdevice, 150
microglia, 151, 169, 170, 240, 241
microglial/neuron co-culture, 151
miRNA, 219
mislocalisation, 136, 199
mitochondria, 118, 149, 194, 225, 238
mitochondrial protein dysfunction, 200
mobility, 331
mode of action, 244
modelling, 292
modifiers, 221
mortality, 111
motor cortex, 183, 256
motor neuron, 138, 139, 140, 183, 225, 226, 247, 261
motor unit, 246
mouse model, 162, 163, 172, 183
MRI/MRSI, 252, 257, 258
multidisciplinary care, 330, 333, 341
multi-ethnic cohort, 128, 296
MUNIX, 252
muscle strength restoration, 226
muscle, 158, 207, 215, 219, 249, 252, 331
mutation, 128, 159
national registry, 110
natural history, 111
NEK1, 118
network analysis, 260
neurodegeneration, 103, 159, 163, 201, 241
neurofilament, 166, 208, 210
neuroimaging, 259, 260, 261
neuroinflammation, 151, 168, 201, 213, 240, 242
neuron, 197
neuronal differentiation, 171
neuron-glia interactions, 223
neuropathology, 183, 290
neuropeptide Y, 227
neurophysiology, 254
neuroprotection, 226, 239, 242, 244
neuropsychology, 116, 254, 304
neurotherapeutic, 229
neurotrophic factor, 141, 177, 182, 232, 279
NIV, 319, 320, 321
NMJ, 175, 177
non viral, 231
non-motor symptoms, 305
nucleocytoplasmic transport, 153, 193
nutrition, 309, 310
nutritional status, 309
oligodendrocytes, 203
oligogenic inheritance, 124
oligonucleotide therapeutics, 222
OPC, 224
Optineurin, 126
outcome measurement, 330
oxidative stress, 149, 166, 167
palliative care, 347
pathogenesis, 202
pathology, 103, 200, 202, 204
pathophysiology, 193
patient insights, 262
PDZD8, 159
peak cough flow, 316
PEG, 312, 313
peripheral immune system, 188
peripheral nervous system, 115
PET, 214
phagocytosis, 197
pharmacokinetics, 277, 284, 287
phase transitions, 155
phenotyping, 126, 293, 295, 296, 297
phosphatidyl inositol signaling, 171
phosphorylation, 199
physiotherapy, 314, 336
plasma, 292
pleotherapy, 244
population-based, 105, 106
pre-symptomatic, 197, 327
prevention, 327
PRO-ACT, 265, 278
probiotic, 282
prognosis, 210, 301, 326, 346
prognostic factor, 110
progression, 214, 292
protein aggregation, 145, 153
protein misfolding, 135, 137, 203, 236
protein, 192
protein-protein interaction, 148
proteomics, 148, 169, 209, 281
proteostasis, 147, 148
QoL (Quality of Life), 109, 275, 299, 302, 333, 334
109, 275, 299, 333, 334
qualitative study, 263
questionnaire/survey, 334, 335
Raman spectroscopy, 159
rat model, 156
recommendations, 312
redox-active protectant, 149
register/registry, 324
regulatory T-cell, 278
reinnervation, 246, 322
reldesemtiv, 273, 274, 275
research, 262
respiration, 321
respiratory care, 313, 320, 324
respiratory function, 272, 303, 311, 314, 316, 317, 318, 325
respiratory tract infections, 318
retrotransposons, 130
riluzole, 274, 299, 305, 343, 344
risk factor, 101, 103, 105, 206
RNA binding protein, 144
RNA processing and dysregulation, 186, 203
Ryanodine receptor, 140
SALS, 129, 130 , 161
screening tool, 188, 306
selectivity, 249
sequencing, 117, 190
Sigma-1 receptor, 149
signaling cascade/pathway, 171
skeletal muscle, 174
sleep-disordered breathing, 316
SMA (spinal muscular atrophy), 221, 291
small molecule drug/screen, 145
SOD1, 128, 129, 144, 145, 146, 147, 175, 201, 204, 221, 233
SOD1G93A mouse model, 144, 168, 174, 232
somatic mutations, 131
speech, 297, 298, 339
spinal cord, 131, 205
splice-switching, 221
splicing, 195
Split hand sign, 248
Split-leg syndrome, 247
SQSTM1, 126, 127, 153
staging, 109
stathmin-2, 198
stem cells, 182, 229, 230, 231, 279, 280, 281, 342
stratification, 110, 133
strenuous physical-activity, 101
stress granule/s, 143, 144, 180
structural biology, 236
study design, 264, 266, 271, 283, 286
sub-Saharan Africa, 104
support, 307, 308, 333
survival, 108, 251, 301, 321, 324, 342
swallowing, 314, 338, 343
symptom management, 346
synapse, 230
synaptic dysfunction, 162
systematic review, 310, 314
TARDBP/TDP-43, 137, 1338, 142, 143, 151, 153, 155, 161, 162, 163, 165,167, 170, 172, 177, 180, 181, 183, 196, 198, 210, 219, 220, 222, 228, 237, 244
tau, 210
TBK1, 126, 162, 163
TDP-43ΔNLS transgenic mice, 219
technology, 297
telemedicine, 330
therapeutic strategies, 144, 218, 224, 225, 237, 264, 280
therapeutic trials, 299
therapy, 170, 231, 271, 278, 332, 344
TIV, 324
TMS, 256
TPPV, 324
tracheostomy, 323
transcriptomics, 187
transfer RNA, 186
transforming growth factor-β, 158
transgenic mouse model, 168, 186, 218, 237
trial design, 266, 269, 271, 272, 273
TrkB receptor, 146
troponin, 215
tyrosine kinase inhibitor, 273
tyrosine kinase receptors, 242
ubiquitin, 148
ultrasound, 249, 251
upper motor neuron/s, 133, 290
variant functional analysis, 160
ventilation, 323, 326
video fluoroscopy, 336
wellbeing, 307
WES, 115, 120, 124, 127, 131
working, 334
zebrafish, 160, 162, 167, 170, 176, 234